Improving the life of our patients with next-generation technologies and individual therapies

  • Focused on novel cancer immunotherapies and respiratory treatments
  • First Austrian biotech company to develop a cancer immunotherapy product through to market
    Approval in 2017 of APN311 for treatment of pediatric neuroblastoma in EU and other countries,
    US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Lead by highly experienced and motivated team with global background


invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline
invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022. invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer immunotherapy activities and all related clinical and preclinical R&D projects. invIOs’ CEO Peter Llewellyn-Davies...
December 16, 2021
APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself Primary objective is to evaluate safety and tolerability of inhaled APN01 Phase 1 trial to enroll about 40 healthy volunteers Additional US Phase 2 trial with intravenous administration of APN01 Press release (EN) | Presseaussendung (DE)
October 12, 2021
The Cancer Revolution
Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed with cancer in their lifetime2, resulting in a stronger-than-ever drive for new efficacious therapies. Our growing knowledge of cancer enables us to develop new technologies...
September 3, 2021